The STING pathway targeting technologies market is anticipated to be worth over USD 2.8 billion by 2
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies
Roots Analysis is pleased to announce the publication of its recent study, titled, “STING Pathway Targeting Therapeutics and Technologies, 2020-2030.”
The report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of therapeutics targeting STING Pathway.
A detailed assessment of the current market landscape of various technology platforms that are being actively used for the development of STING modulators.
Detailed profiles of developers of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products).
An in-depth analysis of more than 280 grants that have been awarded to research institutes engaged in STING pathway targeting therapeutics-related projects.
An analysis of the initiatives of big pharma players engaged in this domain.
An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of STING pathway targeting therapeutics.
A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 – Q1 2020.
An analysis of the partnerships that have been established in this domain, in the recent past.
An analysis of the investments made in this domain.